Metastasis-Free Survival Endpoint Spreads To Labeling With US FDA Approval Of J&J's Erleada

Apalutamide, the first drug approved to treat non-metastatic castration-resistant prostate cancer, will also be the first NDA to have clinical...

      

Related Stories

• US FDA Wants Generic Sponsors To Know If Anything Missing Before Submitting ANDA
• Metastasis-Free Survival Endpoint Spreads To Labeling With US FDA Approval Of J&J's Erleada
• Charleston's Anti-Emetic/Opioid Combo Flops At US FDA Panel Over Postmarketing, Dosage Concerns

 

Original Article: Metastasis-Free Survival Endpoint Spreads To Labeling With US FDA Approval Of J&J's Erleada

More From BioPortfolio on "Metastasis-Free Survival Endpoint Spreads To Labeling With US FDA Approval Of J&J's Erleada"